一次情報の記録
この決算リリースは、F-18標識タウPETイメージング剤であるTAUKLARIFY (florquinitau F-18注射剤)の前回のFDA承認を要約しています。LantheusはPharma Solutions事業を通じてアルツハイマー治療プログラムを支援する一方で、より広範な商業的利用可能性を評価する予定です。
EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Third Quarter 2026 Financial Results • Worldwide revenue of $389.9 million in the third quarter of 2026 • GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 • Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third quarter of 2025 • FDA approves TAUKLARIFY ™ (florquinitau F-18 injection); an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer’s disease • FDA grants final approval for BRAVNETSA ™ (lutetium Lu 177 dotatate); the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA ® for the treatment of adults with soma